IMMUNOGENETHERAPY OF CHRONIC HCV CARRIER CHIMPANZEES

慢性 HCV 携带者黑猩猩的免疫基因治疗

• 批准号: 7562457
• 负责人: KRISHNA H MURTHY
• 金额: $ 7.09万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562457
• 关键词: Acute; Adenoviruses; Animals; Antigens; Carrier State; Chronic; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Hepatitis C; Hepatitis C virus; Immune response; Immunity; Individual; Institution; Pan Genus; Pan troglodytes; Patients; Poxviridae; Recombinants; Recovery; Research; Research Personnel; Resources; Source; T-Lymphocyte; Testing; Treatment Protocols; United States National Institutes of Health; Vaccinated; Vaccines; Viremia; doxorubicin/mitomycin/vinblastine protocol; response; vector

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Vigorous HCV-specific T cell responses are typically observed in patients who recover spontaneously from acute, self-limited hepatitis C. In contrast, T cell responses are weak and narrowly focused in persistently infected patients. It has been proposed that enhancement and/or de novo induction of HCV-specific cellular immune responses in chronically infected individuals will induce HCV clearance and recovery. This hypothesis can only be tested in chimpanzees, the only animals susceptible to HCV infection. We propose to vaccinate 2 HCV carrier chimpanzees with recombinant vectors expressing HCV NS3, NS4 and NS5B to induce HCV-specific T cell responses and to evaluate whether these HCV-specific T cells can impact on HCV carrier state, by reducing or eliminating viremia and/or by controlling HCV antigen expression. The vaccine has 2 components, a recombinant HCV pox-virus (MVA-HCV) and a recombinant HCV adenovirus (Ad-HCV), and will be applied in a prime-boost regimen. The vaccine expresses 3 HCV antigens, namely HCV NS3, NS4 and NS5B. Both adenoviruses and MVA are known to be strong inducers of T-cell immunity. One HCV carrier chimpanzee will be mock vaccinated with vectors that do not express the HCV antigens.

这个子项目是众多研究子项目之一